Hexokinase 2 is dispensable for T cell-dependent immunity

Area of Science:

• Immunology
• Metabolic pathways
• Cancer biology

Background:

• T cells and cancer cells rely on glycolysis for proliferation.
• Hexokinase 2 (HK2) is a key enzyme in glycolysis, upregulated in both cancer and T cells.
• The necessity of HK2 in T cells is unclear, impacting its potential as a cancer therapeutic target.

Purpose of the Study:

• To investigate the necessity of HK2 for T cell function.
• To assess the impact of HK2 inhibition on T cell-mediated immunity and inflammation.
• To identify alternative metabolic targets in T cell leukemia.

Main Methods:

• Genetic ablation of HK2 in mouse T cells using CRISPR-Cas9 technology.
• In vitro and in vivo functional assays of T cells, including immune response and inflammation models.
• RNA-sequencing to compare metabolic gene expression between proliferating T cells and T cell leukemia.

Main Results:

• HK2 is largely dispensable for T cell activation, proliferation, and differentiation in vitro.
• Loss of HK2 does not impair in vivo viral immunity and only slightly affects pathological inflammation.
• HK2 is not essential for regulatory T cell function or hematopoiesis.

Conclusions:

• T cells can function effectively without HK2, supporting its potential as a cancer therapy target.
• HK2 inhibition may offer a therapeutic window in cancer treatment with limited adverse effects on T cells.
• Differential metabolic gene expression in T cell leukemia reveals potential alternative therapeutic targets.